11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Underlying and immediate causes of death in patients with idiopathic pulmonary fibrosis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The most common cause of death of patients with idiopathic pulmonary fibrosis (IPF) has been reported to be the lung disease itself and mortality from IPF appears to be increasing. However, the causes of death in patients with IPF taking into account differences between genders and smoking histories as well as disease progression, have not been previously explored.

          Methods

          Retrospective data from hospital register and death certificates from national database of IPF patients treated in Kuopio University Hospital (KUH) from 2002 to 2012 were collected. Mortality was also explored from the death registry database via ICD-10 code J84 revealing the numbers of deaths from pulmonary fibrosis in Finland from 1998 to 2015.

          Results

          Out of 117 deaths, 26.5% were females and 73.5% males in KUH. The most common underlying causes of death were IPF 67.5% and ischemic heart diseases 14.8%. More males died for reasons other than IPF (39.5%) compared to females (12.9%) ( p = 0.007). Pneumonia as the immediate cause of death was more common in males (27.9%) than in females (3.2%) ( p = 0.004) and in ex-smokers (32.7%) compared to non-smokers (9.3%) ( p = 0.007). Death register based mortality from pulmonary fibrosis is increasing in Finland.

          Conclusions

          Even though the overall mortality was higher in males with IPF, the disease-specific mortality for IPF was higher in females i.e. in males, comorbidities were more often the underlying causes of death. Pneumonia-triggered acute exacerbations of IPF may be associated with smoking and gender since females and non-smokers were less likely to succumb to pneumonia. We conclude that disease progression at the end of life may vary depending on smoking habits and gender.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          A multidimensional index and staging system for idiopathic pulmonary fibrosis.

          Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with an overall poor prognosis. A simple-to-use staging system for IPF may improve prognostication, help guide management, and facilitate research. To develop a multidimensional prognostic staging system for IPF by using commonly measured clinical and physiologic variables. A clinical prediction model was developed and validated by using retrospective data from 3 large, geographically distinct cohorts. Interstitial lung disease referral centers in California, Minnesota, and Italy. 228 patients with IPF at the University of California, San Francisco (derivation cohort), and 330 patients at the Mayo Clinic and Morgagni-Pierantoni Hospital (validation cohort). The primary outcome was mortality, treating transplantation as a competing risk. Model discrimination was assessed by the c-index, and calibration was assessed by comparing predicted and observed cumulative mortality at 1, 2, and 3 years. Four variables were included in the final model: gender (G), age (A), and 2 lung physiology variables (P) (FVC and Dlco). A model using continuous predictors (GAP calculator) and a simple point-scoring system (GAP index) performed similarly in derivation (c-index of 70.8 and 69.3, respectively) and validation (c-index of 69.1 and 68.7, respectively). Three stages (stages I, II, and III) were identified based on the GAP index with 1-year mortality of 6%, 16%, and 39%, respectively. The GAP models performed similarly in pooled follow-up visits (c-index ≥71.9). Patients were drawn from academic centers and analyzed retrospectively. The GAP models use commonly measured clinical and physiologic variables to predict mortality in patients with IPF.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome.

            Although acute exacerbation of idiopathic pulmonary fibrosis (IPF) has become well recognised, the reported incidence and outcomes are highly variable, and risk factors are unknown. The aim of this study was to estimate the incidence, risk factors and impact of acute exacerbations, and other known causes of rapid deterioration. This was a retrospective review of 461 patients with IPF (269 cases were biopsy-proven). The median follow-up period was 22.9 months. Rapid deterioration requiring hospitalisation occurred in 163 (35.4%) patients, with multiple episodes in 42 patients. Acute exacerbation was the most frequent cause (55.2%), followed by infection. The 1- and 3-yr incidences of acute exacerbation were 14.2 and 20.7%, respectively. Never having smoked and low forced vital capacity (FVC) were significant risk factors. The in-hospital mortality rate was 50.0%, and the 1- and 5-yr survival rates from the initial diagnosis were 56.2 and 18.4%, respectively. Acute exacerbation was a significant predictor of poor survival after the initial diagnosis, along with increased age, low FVC and diffusing capacity of the lung for carbon monoxide, and steroid use with or without cytotoxic therapy. 1- and 3-yr incidences of acute exacerbation were 14.2 and 20.7%, respectively. Never having smoked and low FVC were risk factors. Acute exacerbation had a serious impact on the overall survival of the patients with IPF.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The clinical course of patients with idiopathic pulmonary fibrosis.

              Prospective data defining the clinical course in idiopathic pulmonary fibrosis (IPF) are sparse. To analyze the clinical course of patients with mild to moderate IPF. Analysis of data from the placebo group of a randomized, controlled trial evaluating interferon-gamma1b. Academic and community medical centers. 168 patients in the placebo group of a trial evaluating interferon-gamma1b. Measures of physiology and dyspnea assessed at 12-week intervals; hospitalizations; and the pace of deterioration and cause of death over a median period of 76 weeks. Physiologic variables changed minimally during the study. However, 23% of patients required hospitalization for a respiratory disorder and 21% died. Idiopathic pulmonary fibrosis was the primary cause of death in 89% of patients who died, and an apparent acute clinical deterioration preceded death in 47% of these patients. The instrument used to define the pace of deterioration and cause of death was applied retrospectively. Recognition of the common occurrence of acute fatal deterioration in patients with mild to moderate IPF has important implications for monitoring patients and supports early referral for lung transplantation.
                Bookmark

                Author and article information

                Contributors
                +358449713279 , miia.karkkainen@kuh.fi
                hanna.nurmi@kuh.fi
                hannu-pekka.kettunen@kuh.fi
                tuomas.selander@kuh.fi
                minna.purokivi@kuh.fi
                riitta.kaarteenaho@oulu.fi
                Journal
                BMC Pulm Med
                BMC Pulm Med
                BMC Pulmonary Medicine
                BioMed Central (London )
                1471-2466
                11 May 2018
                11 May 2018
                2018
                : 18
                : 69
                Affiliations
                [1 ]ISNI 0000 0001 0726 2490, GRID grid.9668.1, Division of Respiratory Medicine, Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences, , University of Eastern Finland, ; P.O. Box 1627, 70211 Kuopio, Finland
                [2 ]Kuopio City Home Care, Rehabilitation and Medical Services for Elderly, Tulliportinkatu 37E, 70100 Kuopio, Finland
                [3 ]ISNI 0000 0004 0628 207X, GRID grid.410705.7, Center of Medicine and Clinical Research, Division of Respiratory Medicine, , Kuopio University Hospital, ; P.O. Box 100, 70029 KYS Kuopio, Finland
                [4 ]ISNI 0000 0004 0628 207X, GRID grid.410705.7, Department of Clinical Radiology, , Kuopio University Hospital, ; P.O. Box 100, 70029 KYS Kuopio, Finland
                [5 ]ISNI 0000 0004 0628 207X, GRID grid.410705.7, Science Services Center, , Kuopio University Hospital, ; P.O. Box 100, 70029 KYS Kuopio, Finland
                [6 ]ISNI 0000 0004 4685 4917, GRID grid.412326.0, Respiratory Medicine, Research Unit of Internal Medicine, , University of Oulu and Medical Research Center Oulu, Oulu University Hospital, ; P.O. Box 20, 90029 Oulu, Finland
                [7 ]ISNI 0000 0001 0726 2490, GRID grid.9668.1, Kuopio University Hospital and University of Eastern Finland, ; Puijonlaaksontie 2, 70210, P.O. Box 100, 70029 KYS Kuopio, Finland
                Article
                642
                10.1186/s12890-018-0642-4
                5948790
                29751748
                5cc820de-22e7-4fb4-8dba-227859e31330
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 18 December 2017
                : 4 May 2018
                Funding
                Funded by: The Foundation of Finnish Anti-Tuberculosis association
                Funded by: The Organization for Respiratory Health in Finland
                Funded by: Väinö and Laina Kivi Foundation
                Funded by: The Kuopio Region Respiratory Foundation
                Funded by: FundRef http://dx.doi.org/10.13039/100010125, Jalmari ja Rauha Ahokkaan Säätiö;
                Funded by: North Savo Regional Fund of the Finnish Cultural Foundation
                Funded by: the state subsidy of the Kuopio University Hospital
                Funded by: Research Director of Kuopio University Hospital
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2018

                Respiratory medicine
                cause of death,idiopathic pulmonary fibrosis,mortality,acute exacerbation
                Respiratory medicine
                cause of death, idiopathic pulmonary fibrosis, mortality, acute exacerbation

                Comments

                Comment on this article